Axsome Therapeutics (AXSM) Other Accumulated Expenses (2015 - 2020)

Axsome Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $1.0 million for Q3 2020.

• In Q3 2020, Other Accumulated Expenses rose 30.12% year-over-year to $1.0 million; the TTM figure through Sep 2020 stood at $1.0 million (up 30.12% YoY), while the FY2019 annual figure was $683178.0, up 29.98% from the prior year.
• Other Accumulated Expenses came in at $1.0 million for Q3 2020 at Axsome Therapeutics, down from $1.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q2 2020 to a low of $168004.0 in Q2 2016.
• A 5-year average of $609610.1 and a median of $531021.0 in 2019 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 370.74% in 2016 and tumbled 43.33% in 2017, its largest moves.
• Axsome Therapeutics' Other Accumulated Expenses stood at $587339.0 in 2016, then tumbled by 43.33% to $332824.0 in 2017, then surged by 57.93% to $525613.0 in 2018, then rose by 29.98% to $683178.0 in 2019, then surged by 50.9% to $1.0 million in 2020.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.0 million, $1.2 million, and $1.1 million for Q3 2020, Q2 2020, and Q1 2020 respectively.

Peer Comparison